Eczema Treatment Options: Dupilumab, Topical Steroids, and Barrier Repair

The Most Common Inflammatory Skin Disease Burdens Millions From Infancy

Atopic dermatitis (AD) — commonly called eczema — is the most prevalent chronic inflammatory skin disease in the world, affecting 15–20% of children and 2–10% of adults. It is characterized by intensely pruritic, dry, inflamed skin that follows a relapsing-remitting course. In severe cases, incessant itch disrupts sleep, impairs concentration, causes significant psychological distress, and drives secondary bacterial infections (most commonly Staphylococcus aureus, which colonizes the skin of over 90% of AD patients during flares). The condition is part of the "atopic march" — a developmental progression that frequently includes allergic rhinitis and asthma — reflecting shared pathophysiological mechanisms of type 2 immune dysregulation.

Until 2017, there was no systemic medication specifically approved for atopic dermatitis. The subsequent decade has transformed treatment.

The Skin Barrier: The Foundation of All Eczema Treatment

The primary defect in atopic dermatitis is not simply excess inflammation — it begins with a defective epidermal skin barrier. Loss-of-function mutations in the FLG gene encoding filaggrin, a structural protein essential for corneocyte integrity, are found in 20–30% of European AD patients and substantially increase disease risk. Even in patients without filaggrin mutations, AD skin shows reduced ceramide content, increased transepidermal water loss (TEWL), and disrupted tight junctions that allow allergen penetration and microbial colonization. This barrier deficiency activates dendritic cells and initiates the type 2 immune response that drives inflammation.

Barrier repair is therefore foundational to all AD treatment — not an afterthought:

• Emollients (moisturizers): Applied at least twice daily, ideally to damp skin within 3 minutes of bathing; thick creams and ointments (petrolatum, ceramide-containing formulations) outperform lotions for TEWL reduction; PREVENT trial data suggest early intensive moisturization may reduce AD development in high-risk infants
• Bathing practices: Short (5–10 minute), lukewarm baths or showers followed by immediate moisturizer application; dilute bleach baths (sodium hypochlorite 0.005%) reduce bacterial colonization and reduce AD severity in multiple RCTs; frequency: 2–3 times per week
• Trigger avoidance: Common triggers include wool and synthetic fabrics (use soft cotton), fragranced products, excessive sweating, low humidity environments, and specific allergens identified via allergy testing

Topical Therapies: Corticosteroids and the Alternatives

Topical corticosteroids (TCS) remain the cornerstone of acute AD flare management, with over 60 years of clinical evidence supporting their efficacy and safety when used appropriately. The "finger-tip unit" guides dosing (one unit covers an area twice the size of an adult's hand). Prolonged use on sensitive areas risks skin atrophy; patients often develop corticophobia — exaggerated fear of TCS side effects — that leads to undertreatment and worse outcomes.

The Dupilumab Revolution: Targeting IL-4 and IL-13

Dupilumab (Dupixent) is a fully human monoclonal antibody that blocks the shared alpha subunit of the IL-4 and IL-13 receptors, simultaneously shutting down both cytokines that drive the central Th2 inflammatory cascade in AD. When it received FDA approval in 2017 as the first biologic approved for AD, it represented a paradigm shift: in phase 3 trials (SOLO-1, SOLO-2, CHRONOS), dupilumab achieved IGA 0/1 (clear or almost clear skin) in 35–40% of patients and EASI-75 (75% reduction in Eczema Area and Severity Index) in 50–55% of patients at 16 weeks, compared to 8–10% placebo rates. Crucially, it also dramatically reduced itch scores (often within the first week) and significantly improved sleep and quality of life measures.

Dupilumab is administered subcutaneously every 2 weeks and is approved for adults, adolescents, and children as young as 6 months. Side effects include injection site reactions, ocular surface disease (conjunctivitis, blepharitis) in approximately 10% of patients — a unique side effect class not seen with other biologics — and nasopharyngitis. It carries no immunosuppression warnings regarding infections or malignancy.

Newer Biologics and JAK Inhibitors

The success of dupilumab prompted development of additional biologics and oral small molecules for AD:

• Tralokinumab (Adbry): IL-13-specific monoclonal antibody; FDA approved 2021; every-other-week dosing; EASI-75 in ~25–38% at week 16; lower conjunctivitis rates than dupilumab; can be extended to monthly dosing in responders
• Lebrikizumab (Ebglyss): IL-13-specific monoclonal antibody; FDA approved 2024; every-other-week for induction, then monthly maintenance; strong efficacy data
• Abrocitinib (Cibinqo): Oral JAK1-selective inhibitor; FDA approved 2022; 200 mg dose achieved IGA 0/1 in 44% at week 12; rapid onset (itch improvement within days); venous thromboembolism, cardiovascular, and malignancy label warnings apply (same class as other JAK inhibitors); restricted to refractory patients after other systemic therapies
• Upadacitinib (Rinvoq): Oral JAK1-selective inhibitor; FDA approved for AD 2022; highest clinical response rates of any approved AD therapy (IGA 0/1 approximately 50% at 16 weeks); same class warnings as abrocitinib

Allergen immunotherapy (subcutaneous or sublingual) targeting house dust mite allergens has emerging evidence in AD — a subset of patients with IgE-mediated sensitization to house dust mites show significant improvement with immunotherapy, suggesting a disease-modifying approach complementary to symptomatic treatment.

This article is for informational purposes only. Consult a qualified healthcare professional before making medical decisions.